Mustang Bio to Present at the Raymond James Human Health Innovation Conference
June 16, 2021 08:30 ET
|
Mustang Bio, Inc.
WORCESTER, Mass., June 16, 2021 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in...
Mustang Bio Announces Updated Interim Phase 1/2 Data for MB-106 CD20-Targeted CAR T in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphomas and Chronic Lymphocytic Leukemia
June 11, 2021 06:30 ET
|
Mustang Bio, Inc.
Data presented at the European Hematology Association 2021 Virtual Congress show favorable safety profile and compelling clinical activity 93% overall response rate and 67% complete response rate in...
Mustang Bio to Host Key Opinion Leader Webinar on MB-106 CD20-Targeted CAR T for the Treatment of High-Risk B-Cell Non-Hodgkin Lymphomas and Chronic Lymphocytic Leukemia
June 07, 2021 08:00 ET
|
Mustang Bio, Inc.
Webinar to be held Tuesday, June 15, 2021, at 1:00 p.m. ET WORCESTER, Mass., June 07, 2021 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical...
Mustang Bio and City of Hope Announce First Patient Dosed in Phase 1 Clinical Trial of MB-101 (IL13Rα2-specific CAR T cells) to Treat Leptomeningeal Brain Tumors
May 18, 2021 08:00 ET
|
Mustang Bio, Inc.
WORCESTER, Mass. and DUARTE, Calif., May 18, 2021 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical...
Mustang Bio Reports First Quarter 2021 Financial Results and Recent Corporate Highlights
May 14, 2021 16:30 ET
|
Mustang Bio, Inc.
WORCESTER, Mass., May 14, 2021 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in...
Mustang Bio Announces MB-106 CD20-Targeted CAR T Data Selected for Presentation at European Hematology Association 2021 Virtual Congress
May 12, 2021 12:45 ET
|
Mustang Bio, Inc.
WORCESTER, Mass., May 12, 2021 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in...
Mustang Bio Announces FDA Acceptance of IND Application for MB-106, a CD20-Targeted CAR T Therapy
May 10, 2021 07:30 ET
|
Mustang Bio, Inc.
The Phase 1/2 multicenter study to assess the safety, tolerability and efficacy of MB-106 in patients with relapsed or refractory CD20+ B-cell non-Hodgkin lymphoma and chronic lymphocytic leukemia is...
Mustang Bio to Participate in Chardan’s 5th Annual Genetic Medicines Manufacturing Summit
April 21, 2021 08:00 ET
|
Mustang Bio, Inc.
WORCESTER, Mass., April 21, 2021 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in...
Mustang Bio Reports Full-Year 2020 Financial Results and Recent Corporate Highlights
March 24, 2021 16:30 ET
|
Mustang Bio, Inc.
NEW YORK, March 24, 2021 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and...
Mustang Bio to Participate in Three March 2021 Virtual Investor Conferences
March 04, 2021 08:00 ET
|
Mustang Bio, Inc.
WORCESTER, Mass., March 04, 2021 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in...